Cargando…
A Smartphone Healthcare Application, CALO mama Plus, to Promote Weight Loss: A Randomized Controlled Trial
Mobile applications are increasingly used in healthcare. We have developed a smartphone healthcare application, CALO mama Plus, that can register daily diet, exercise, mood, and sleep quality, calculate dietary intake, and provide advice using artificial intelligence technology. This 3-month randomi...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655114/ https://www.ncbi.nlm.nih.gov/pubmed/36364870 http://dx.doi.org/10.3390/nu14214608 |
_version_ | 1784829106305630208 |
---|---|
author | Nakata, Yoshio Sasai, Hiroyuki Gosho, Masahiko Kobayashi, Hiroyuki Shi, Yutong Ohigashi, Tomohiro Mizuno, Shinichiro Murayama, Chiaki Kobayashi, Satomi Sasaki, Yuki |
author_facet | Nakata, Yoshio Sasai, Hiroyuki Gosho, Masahiko Kobayashi, Hiroyuki Shi, Yutong Ohigashi, Tomohiro Mizuno, Shinichiro Murayama, Chiaki Kobayashi, Satomi Sasaki, Yuki |
author_sort | Nakata, Yoshio |
collection | PubMed |
description | Mobile applications are increasingly used in healthcare. We have developed a smartphone healthcare application, CALO mama Plus, that can register daily diet, exercise, mood, and sleep quality, calculate dietary intake, and provide advice using artificial intelligence technology. This 3-month randomized controlled trial tested the hypothesis that CALO mama Plus could promote body weight reduction in Japanese adults with overweight or obesity. We recruited office workers as participants. The key eligibility criteria were an age of 20–65 years and a body mass index of 23–40 kg/m(2). The primary outcome was body weight change over 3 months. We enrolled 141 participants and randomly assigned them to the intervention (n = 72) and control (n = 69) groups. The intervention group used CALO mama Plus, and the control group did not receive any intervention. The change in body weight was −2.4 ± 4.0 kg and −0.7 ± 3.3 kg in the intervention and control groups, respectively. An analysis of covariance adjusted for related variables showed a significant between-group difference in body weight change (−1.60 kg; 95% confidence interval −2.83 to −0.38; p = 0.011). The present study suggests that CALO mama Plus effectively promotes weight loss. |
format | Online Article Text |
id | pubmed-9655114 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96551142022-11-15 A Smartphone Healthcare Application, CALO mama Plus, to Promote Weight Loss: A Randomized Controlled Trial Nakata, Yoshio Sasai, Hiroyuki Gosho, Masahiko Kobayashi, Hiroyuki Shi, Yutong Ohigashi, Tomohiro Mizuno, Shinichiro Murayama, Chiaki Kobayashi, Satomi Sasaki, Yuki Nutrients Article Mobile applications are increasingly used in healthcare. We have developed a smartphone healthcare application, CALO mama Plus, that can register daily diet, exercise, mood, and sleep quality, calculate dietary intake, and provide advice using artificial intelligence technology. This 3-month randomized controlled trial tested the hypothesis that CALO mama Plus could promote body weight reduction in Japanese adults with overweight or obesity. We recruited office workers as participants. The key eligibility criteria were an age of 20–65 years and a body mass index of 23–40 kg/m(2). The primary outcome was body weight change over 3 months. We enrolled 141 participants and randomly assigned them to the intervention (n = 72) and control (n = 69) groups. The intervention group used CALO mama Plus, and the control group did not receive any intervention. The change in body weight was −2.4 ± 4.0 kg and −0.7 ± 3.3 kg in the intervention and control groups, respectively. An analysis of covariance adjusted for related variables showed a significant between-group difference in body weight change (−1.60 kg; 95% confidence interval −2.83 to −0.38; p = 0.011). The present study suggests that CALO mama Plus effectively promotes weight loss. MDPI 2022-11-02 /pmc/articles/PMC9655114/ /pubmed/36364870 http://dx.doi.org/10.3390/nu14214608 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Nakata, Yoshio Sasai, Hiroyuki Gosho, Masahiko Kobayashi, Hiroyuki Shi, Yutong Ohigashi, Tomohiro Mizuno, Shinichiro Murayama, Chiaki Kobayashi, Satomi Sasaki, Yuki A Smartphone Healthcare Application, CALO mama Plus, to Promote Weight Loss: A Randomized Controlled Trial |
title | A Smartphone Healthcare Application, CALO mama Plus, to Promote Weight Loss: A Randomized Controlled Trial |
title_full | A Smartphone Healthcare Application, CALO mama Plus, to Promote Weight Loss: A Randomized Controlled Trial |
title_fullStr | A Smartphone Healthcare Application, CALO mama Plus, to Promote Weight Loss: A Randomized Controlled Trial |
title_full_unstemmed | A Smartphone Healthcare Application, CALO mama Plus, to Promote Weight Loss: A Randomized Controlled Trial |
title_short | A Smartphone Healthcare Application, CALO mama Plus, to Promote Weight Loss: A Randomized Controlled Trial |
title_sort | smartphone healthcare application, calo mama plus, to promote weight loss: a randomized controlled trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655114/ https://www.ncbi.nlm.nih.gov/pubmed/36364870 http://dx.doi.org/10.3390/nu14214608 |
work_keys_str_mv | AT nakatayoshio asmartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial AT sasaihiroyuki asmartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial AT goshomasahiko asmartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial AT kobayashihiroyuki asmartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial AT shiyutong asmartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial AT ohigashitomohiro asmartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial AT mizunoshinichiro asmartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial AT murayamachiaki asmartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial AT kobayashisatomi asmartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial AT sasakiyuki asmartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial AT nakatayoshio smartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial AT sasaihiroyuki smartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial AT goshomasahiko smartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial AT kobayashihiroyuki smartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial AT shiyutong smartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial AT ohigashitomohiro smartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial AT mizunoshinichiro smartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial AT murayamachiaki smartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial AT kobayashisatomi smartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial AT sasakiyuki smartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial |